CXCR4 and neuroendocrine carcinoma: To evaluate the diagnostic potential of CXCR4 labeling in dedifferentiated tumors, Weich et al. confronted 18F-FDG and 68Ga-Pentixafor PET/CT in 11 patients newly diagnosed from GEP-NEC and studied IHC expression of CXCR4.